645 completed, 182 unknown, 174 recruiting, 142 active not recruiting. 1343 Phase 3, 166 Phase 2.
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma | Phase 3 | Not yet recruiting | Bnai Zion Medical Center | 60 | 2027-08-01 | 2026-09-30 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Linvoseltamab, Daratumumab, Bortezomib - Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 382 | 2026-12-18 | 2026-10-28 |
| A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma | Phase 3 | Not yet recruiting | Janssen Research & Development, LLC | 1000 | 2026-12-14 | 2026-10-29 |
| Evaluation of Iopofosine I 131 vs. R-CD in WM Patients Iopofosine I 131, Rituximab (active comparator), Cyclophosphamate - Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia | Phase 3 | Not yet recruiting | Cellectar Biosciences, Inc. | 219 | 2026-12-01 | 2026-08-14 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). ICP-248, Pirtobrutinib, Orelabrutinib - Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 280 | 2026-10-01 | 2026-08-25 |
| Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma Orelabrutinib, ICP-248 - Relapsed/Refractory Marginal Zone Lymphoma (MZL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 292 | 2026-10-01 | 2026-10-27 |
| A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM) | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-09-24 | 2026-10-21 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
Showing 20 of 1343. Sign in to see all of them.
Multiple Myeloma (382) · Lymphoma (225) · Lymphoma, Follicular (218) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (198) · Lymphoma, Large B-Cell, Diffuse (184) · Lymphoma, Non-Hodgkin (183) · Leukemia, Lymphocytic, Chronic, B-Cell (176) · Leukemia (112) · Hodgkin Disease (96) · Lymphoma, Mantle-Cell (86) · Recurrence (84) · Burkitt Lymphoma (76) · Lymphoma, B-Cell, Marginal Zone (71) · Neoplasms, Plasma Cell (68) · Leukemia, Myeloid, Acute (67)
Immune System Diseases (1336) · Hemic and Lymphatic Diseases (1329) · Immunoproliferative Disorders (1287) · Neoplasms by Histologic Type (1275) · Neoplasms (1222) · Lymphatic Diseases (1001) · Hematologic Diseases (760) · Lymphoma (463) · Cardiovascular Diseases (418) · Blood Protein Disorders (413) · Vascular Diseases (412) · Paraproteinemias (405) · Hemorrhagic Disorders (401) · Hemostatic Disorders (396)
Dexamethasone (279) · Cyclophosphamide (267) · Rituximab (263) · Vincristine (189) · Doxorubicin (179) · Prednisone (162) · Lenalidomide (144) · Bortezomib (122) · Cytarabine (99) · Etoposide (99) · Methotrexate (95) · Radiotherapy (71) · Melphalan (68) · Bendamustine Hydrochloride (67) · daratumumab (63)
Children's Oncology Group (34) · Hoffmann-La Roche (33) · Janssen Research & Development, LLC (33) · Celgene (30) · National Cancer Institute (NCI) (28) · Assistance Publique - Hôpitaux de Paris (22) · Amgen (21) · Novartis Pharmaceuticals (20) · Pfizer (20) · European Organisation for Research and Treatment of Cancer - EORTC (19) · GlaxoSmithKline (16) · Fondazione Italiana Linfomi - ETS (14) · M.D. Anderson Cancer Center (14) · Alliance for Clinical Trials in Oncology (13) · Merck Sharp & Dohme LLC (13)
United States (606) · France (365) · Germany (331) · Italy (325) · United Kingdom (323) · Canada (306) · Spain (298) · Australia (273) · China (272) · Belgium (260) · Poland (246) · Czechia (196) · Netherlands (184) · Israel (180) · Austria (171)
Mary Horowitz, MD (7) · Michael Hallek, MD (7)
PMID 40135712, PMID 39121442, PMID 22689675, PMID 32632956, PMID 32816215, PMID 33242441, PMID 37505794, PMID 38620092, PMID 26373676, PMID 28751558, PMID 31221778, PMID 33288485, PMID 34289038, PMID 37890117, PMID 39563886, PMID 40266025, PMID 41671463, PMID 23897961, PMID 27282998, PMID 30010775, PMID 31196847, PMID 33131249, PMID 34515338, PMID 34865212, PMID 35985959, PMID 37341189, PMID 38023148, PMID 38446568, PMID 38502198, PMID 39229471, PMID 40501401, PMID 41074963, PMID 42699559, PMID 11807147, PMID 15812540, PMID 16754935, PMID 18799726, PMID 19901114, PMID 20032498, PMID 20679620, PMID 21160068, PMID 21195303, PMID 21228328, PMID 21273172, PMID 21791470, PMID 22674807, PMID 23065509, PMID 23233721, PMID 24117042, PMID 24687837
2023 (47), U10CA098543 (18), 2014 (17), 2015 (16), 2016 (15), 2025 (15), 2009 (14), 2017 (14), 2005 (11), 2019 (11), U10CA021115 (11), U10CA180886 (11), 2008 (10), 2018 (10), U10CA180820 (10)